Zenas BioPharma Inc logo

Zenas BioPharma Inc

ZBIO
Healthcare|Biotechnology|USA
$28.73
-0.69 (-2.34%)
Tangible Book
$5.38

Clinical Trials (10)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT05662241
A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease
IgG4 Related Disease
P3
Active194RCT, Double-blindObexelimab
NCT07067463
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
P3
Recruiting705RCT, Double-blindOrelabrutinib, Placebo
NCT05786573
A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre)
Warm Autoimmune Hemolytic Anemia
P3
Active134RCT, Double-blindObexelimab, Obexelimab
NCT07299019
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
P3
Recruiting990RCT, Double-blindOrelabrutinib, Placebo
NCT06564311
A Study of Obexelimab in Patients With Relapsing Multiple Sclerosis (MoonStone)
Relapsing Multiple Sclerosis
P2
Active93RCT, Double-blindObexelimab, Placebo
NCT06559163
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
P2
Recruiting190RCT, Double-blindObexelimab, Placebo
NCT05638854
A Study to Evaluate Safety and Pharmacokinetics of ZB002 in Healthy Participants and Participants With Rheumatoid Arthritis
Healthy Volunteers, Rheumatoid Arthritis
P1
Recruiting72RCT, Double-blindZB002, Placebo, ZB002, Placebo
NCT05794516
A Safety and Pharmacokinetics Study of ZB004 in Healthy Participants
Healthy Volunteers
P1
Completed40RCT, Double-blindZB004, Placebo
NCT05776121
Study of ZB001 in Chinese Patients With Thyroid Eye Disease
Thyroid Eye Disease
P1
Completed17Open-labelZB001 for injection, ZB001 for injection
NCT05542303
A Safety, Tolerability and Pharmacokinetics Study of ZB001 in Healthy Subjects
Healthy Volunteers
P1
Completed24Open-labelZB001 for injection, ZB001 for injection, ZB001 for injection
Zenas BioPharma Inc (ZBIO) BioScore & Pipeline | BioStockEdge